<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296334</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2010-115</org_study_id>
    <secondary_id>2010-022903-23</secondary_id>
    <nct_id>NCT01296334</nct_id>
  </id_info>
  <brief_title>Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine</brief_title>
  <acronym>PASORII</acronym>
  <official_title>Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine Following an Experimental Inflammatory Injury in Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mads u werner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norpharma A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tissue injury is associated with pain from the injured site (primary hyperalgesia) and pain
      from non-injured tissue in the vicinity of the trauma (secondary hyperalgesia). In the
      present study we investigate primary and secondary hyperalgesia in healthy volunteers
      following an experimental first degree burn injury.

      The objectives are:

        -  to compare analgesic and anti-hyperalgesic effects of two opioids (morphine and
           buprenorphine).

        -  to investigate if these effects are related to the volunteers individual pain
           sensitivity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to:

      Ravn P, Secher EL, Skram U, Therkildsen T, Christrup LL, Werner MU (2013) Morphine- and
      buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a
      double-blind, randomized, placebo-controlled, five-arm crossover study. J Pain Res 6: 23-38.
      10.2147/JPR.S36827 [doi];jpr-6-023 [pii].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic and antihyperalgesic effects</measure>
    <time_frame>0 to 180 min after a first degree burn injury</time_frame>
    <description>Analgesic effect is assessed by change in primary hyperalgesia (pain rating [VAS]) Antihyperalgesic effect is assessed by reduction in area of hyperalgesia (sq. cm) VAS-area under curve is calculated for 0, 60, 120 and 180 min after first degree burn injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in analgesic/antihyperalgesic profile between pain-sensitive and pain-non-sensitive individuals</measure>
    <time_frame>0-180 min after first degree burn injury</time_frame>
    <description>The ratios between areas under curve (0-180 min after first degree burn injury) for analgesic effect assessed by change in primary hyperalgesia (pain rating VAS])and antihyperalgesic effect assessed by reduction in area of hyperalgesia (sq. cm).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>morphine low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>morphine infusion 10 mg over a 210 min period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>morphine infusion 20 mg over a 210 min period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>buprenorphine infusion 0.3 mg over a 210 min period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>buprenorphine infusion 0.6 mg over a 210 min period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (normal saline) infusion 0.6 mg over a 210 min period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine LO</intervention_name>
    <description>intravenous infusion, 10 mg, once, 4 hours</description>
    <arm_group_label>morphine low dose</arm_group_label>
    <other_name>Morfin SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Hi</intervention_name>
    <description>intravenous infusion, 20 mg, once, 4 hours</description>
    <arm_group_label>morphine high dose</arm_group_label>
    <other_name>Morfin SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine LO</intervention_name>
    <description>intravenous infusion, 0.3 mg, once, 4 hours</description>
    <arm_group_label>buprenorphine low dose</arm_group_label>
    <other_name>Temgesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Hi</intervention_name>
    <description>intravenous infusion, 0.6 mg, once, 4 hours</description>
    <arm_group_label>buprenorphine high dose</arm_group_label>
    <other_name>Temgesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>intravenous infusion, 0.9% saline, once, 4 hours</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>0.9% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy individuals

          -  adequate psychomotor performance to perform pain tests

          -  pain-sensitive or pain-nonsensitive according to prespecified criteria

        Exclusion Criteria:

          -  known allergy to morphine or buprenorphine

          -  prior adverse experiences with opioids

          -  history of abuse

          -  females not taking P-pills

          -  skin lesions on the test-sites

          -  suffering from chronic pain

          -  medication with analgesics

          -  BMI &gt; 28

          -  smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mads U Werner, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Multidisciplinary Pain Centre 7612, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen O</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lona L Christrup, MSc , PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmaceutical Faculty, Copenhagen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zelo Phase One Clinical Trial Unit, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Koppert W, Ihmsen H, Körber N, Wehrfritz A, Sittl R, Schmelz M, Schüttler J. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005 Nov;118(1-2):15-22. Epub 2005 Sep 9.</citation>
    <PMID>16154698</PMID>
  </reference>
  <results_reference>
    <citation>Ravn P, Secher EL, Skram U, Therkildsen T, Christrup LL, Werner MU. Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study. J Pain Res. 2013;6:23-38. doi: 10.2147/JPR.S36827. Epub 2013 Jan 9.</citation>
    <PMID>23359655</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>mads u werner</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>opioids</keyword>
  <keyword>analgesia</keyword>
  <keyword>secondary hyperalgesia</keyword>
  <keyword>quantitative sensory testing</keyword>
  <keyword>inflammatory injury</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

